Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to 0.64.

  • Neurocrine Biosciences' Asset Utilization Ratio fell 98.48% to 0.64 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.64, marking a year-over-year decrease of 98.48%. This contributed to the annual value of 0.69 for FY2025, which is 137.66% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Asset Utilization Ratio stood at 0.64, which was down 98.48% from 0.66 recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Asset Utilization Ratio ranged from a high of 0.66 in Q2 2025 and a low of 0.54 during Q3 2021
  • Over the past 4 years, Neurocrine Biosciences' median Asset Utilization Ratio value was 0.62 (recorded in 2023), while the average stood at 0.61.
  • Its Asset Utilization Ratio has fluctuated over the past 5 years, first tumbled by 2236.08% in 2021, then soared by 1050.69% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Asset Utilization Ratio (Quarter) stood at 0.54 in 2021, then rose by 14.96% to 0.62 in 2023, then grew by 4.95% to 0.65 in 2024, then dropped by 0.98% to 0.64 in 2025.
  • Its Asset Utilization Ratio stands at 0.64 for Q4 2025, versus 0.66 for Q3 2025 and 0.66 for Q2 2025.